Yandi Gao
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
66
Citations
1,312
Est. group size
~10
Recurring co-author estimate
Active years
13
Publishing since 2013
Yandi Gao's work focuses on non-small cell lung cancer (NSCLC), particularly how tumor cells become resistant to targeted drugs that block signaling proteins like EGFR and KRAS. The research examines specific molecular players (such as CXCR7, MCL1, and STK11) and drug strategies (like BET bromodomain inhibitors) that influence how cancer cells respond or adapt to treatment. This work sits at the intersection of cancer biology, genetics, and pharmacology, aiming to identify ways to overcome drug resistance in lung cancer.
Publication counts have fluctuated over the last decade, with notable spikes in 2018 and especially 2023, suggesting bursts of productivity tied to specific project completions rather than a steadily increasing or decreasing trend.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Data from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Methods from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Supplementary Figures from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Supplementary Methods from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Supplementary Figures from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Data from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Data from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
2023
- Supplementary Figures S1-S6 from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Figure Legends from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Materials and Method from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Table 1 from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Table 1 from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Materials and Method from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Figures S1-S6 from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Supplementary Figure Legends from CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
2023
- Molecular Therapy×4
- Blood×4
- The Journal of Immunology×4
- Figshare×4
- Cancer Research×2
- Christian S. Wright
Biochemistry, Genetics and Molecular Biology · Indiana University
- C. Gabel
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Anthony A. Stephenson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Arthur Luhur
Biochemistry, Genetics and Molecular Biology · Indiana University
- Daniel Mariyappa
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile